Table 15d. Drug Interactions between CCR5 Antagonist and Other Drugs (Updated January 10, 2011)

This table provides information relating to pharmacokinetic interactions between MVC and non-ARV drugs. For interactions among ARV agents and for dosing recommendations, please refer to Table 16b.

| Concomitant Drug Class/Name | CCR5 Antagonist | Effect on CCR5 Antagonist or Concomitant Drug Concentrations | Dosing Recommendations and Clinical Comments | | |
|---|-----------------|--|--|--|--|
| Anticonvulsants | | | | | |
| Carbamazepine Phenobarbital Phenytoin | MVC | ↓ MVC possible | If used without a strong CYP3A inhibitor, use MVC 600 mg BID or an alternative antiepileptic agent. | | |
| Antifungal | | | | | |
| Itraconazole | MVC | ↑ MVC possible | Dose: MVC 150 mg BID | | |
| Ketoconazole | MVC | MVC AUC ↑ 400% | Dose: MVC 150 mg BID | | |
| Voriconazole | MVC | ↑ MVC possible | Consider dose reduction to MVC 150 mg BID | | |
| Antimycobacterials | | | | | |
| Clarithromycin | MVC | ↑ MVC possible | Dose: MVC 150 mg BID | | |
| Rifabutin | MVC | ↓ MVC possible | If used without a strong CYP3A inducer or inhibitor, use MVC 300 mg BID. If used with a strong CYP3A inhibitor, use MVC 150 mg BID. | | |
| Rifampin | MVC | MVC AUC ↓ 64% | Coadministration is not recommended. If coadministration is necessary use MVC 600 mg BID. If coadministered with a strong CYP3A inhibitor, use MVC 300 mg BID. | | |
| Herbal Products | | | | | |
| St. John's wort | MVC | ↓ MVC possible | Coadministration is not recommended. | | |
| Hormonal Contraceptives | | | | | |
| Hormonal contraceptives | MVC | No significant effect on ethinyl estradiol or levonorgestrel | Safe to use in combination | | |
| Narcotics/Treatment for Opioid Dependence | | | | | |
| Methadone | MVC | No data | | | |

Acronyms: ARV = antiretroviral, AUC = area under the curve, BID = twice daily, CYP = cytochrome P, MVC = maraviroc

Table 15e. Drug Interactions between Integrase Inhibitor and Other Drugs (Updated January 10, 2011)

| Concomitant Drug Class/Name | Integrase Inhibitor | Effect on Integrase Inhibitor or Concomitant Drug Concentrations | Dosing Recommendations and Clinical Comments | | |
|---|---------------------|---|---|--|--|
| Acid Reducers | | | | | |
| Omeprazole | RAL | RAL AUC \uparrow 212%, $C_{max} \uparrow$ 315%, and $C_{min} \uparrow$ 46% | No dosage adjustment recommended | | |
| Antimycobacterials | | | | | |
| Rifabutin | RAL | RAL AUC \uparrow 19%, $C_{max} \uparrow$ 39%, and $C_{min} \downarrow 20\%$ | No dosage adjustment recommended | | |
| Rifampin | RAL | RAL AUC \downarrow 40% and $C_{min} \downarrow$ 61% with RAL 400 mg Rifampin with RAL 800 mg BID compared with RAL 400 mg BID alone: RAL AUC \uparrow 27% and $C_{min} \downarrow$ 53% | Dose: RAL 800 mg BID Monitor closely for virologic response. | | |
| Hormonal Contraceptives | | | | | |
| Hormonal contraceptives | RAL | No clinically significant effect | Safe to use in combination | | |
| Narcotics/Treatment for Opioid Dependence | | | | | |
| Methadone | RAL | No significant effect | No dosage adjustment necessary | | |

Acronyms: AUC = area under the curve, BID = twice daily, C_{max} = maximum plasma concentration, C_{min} = minimum plasma concentration, RAL = raltegravir